A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
ID Number 08-0098Principal Investigator(s)
Michael E Farkouh
Department(s) or Division(s)
The Zena and Michael A. Wiener Cardiovascular Institute
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre-randomisation period during which PET/CT and MRI will be conducted, patients will be randomized to receive either RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at intervals during the study. The anticipated time on study treatment is 2 years, and the target sample size is 100 individuals.
Recruiting Patients: No